Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in BOLT held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Sofinnova Investments, Inc. | 138K | $556K | 0.0% | 7.167% | 0.03% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 77K | $312K | +40.4% | 4.019% | 0.00% |
| 3 | Vivo Capital, LLC | 72K | $293K | 0.0% | 3.769% | 0.02% |
| 4 | Pivotal bioVenture Partners Investment Advisor LLC | 43K | $172K | -55.0% | 2.216% | 0.06% |
| 5 | T3 Companies, LLC | 38K | $154K | 0.0% | 1.978% | 0.21% |
| 6 | Board of Trustees of The Leland Stanford Junior University | 36K | $145K | 0.0% | 1.872% | 0.02% |
| 7 | PFIZER INC | 31K | $137K | 0.0% | 1.629% | 0.06% |
| 8 | Lynx1 Capital Management LP | 31K | $124K | β | 1.603% | 0.02% |
| 9 | Nan Fung Group Holdings Ltd | 29K | $118K | -49.9% | 1.522% | 0.10% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 29K | $116K | +53.1% | 1.498% | 0.00% |
| 11 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 28K | $111K | +34.2% | 1.431% | 0.10% |
| 12 | Shay Capital LLC | 15K | $60K | -2.4% | 0.776% | 0.01% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12K | $47K | β | 0.607% | 0.00% |
| 14 | CITADEL ADVISORS LLC | 10K | $41K | β | 0.526% | 0.00% |
| 15 | BlackRock, Inc. | 10K | $39K | 0.0% | 0.505% | 0.00% |
| 16 | VANGUARD CAPITAL MANAGEMENT LLC | 7K | $29K | β | 0.367% | 0.00% |
| 17 | MORGAN STANLEY | 3K | $13K | +1.9% | 0.166% | 0.00% |
| 18 | VANGUARD FIDUCIARY TRUST CO | 3K | $13K | β | 0.161% | 0.00% |
| 19 | Tower Research Capital LLC (TRC) | 1K | $4K | +51.2% | 0.057% | 0.00% |
| 20 | UBS Group AG | 787 | $3K | +52.8% | 0.041% | 0.00% |
| 21 | Vanguard Global Advisers, LLC | 24 | $97 | β | 0.001% | 0.00% |
| 22 | SBI Securities Co., Ltd. | 10 | $40 | 0.0% | 0.001% | 0.00% |
| 23 | BARCLAYS PLC | 6 | $24 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in BOLT β a direct measure of their conviction.
Filings activity in BOLT during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new BOLT position in Q1 2026
Institutions that fully closed their BOLT position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 23 | +9.5% | 28.39% | 9.21 pp | $2M | 24% |
| Q4 2025 | 21 | 8.7% | 37.60% | 10.47 pp | $3M | 22% |
| Q3 2025 | 23 | 12% | 48.07% | 10.11 pp | $4M | 17% |
| Q2 2025 | 26 | 16% | 58.18% | 25.41 pp | $5M | 30% |
| Q1 2025 | 31 | 21% | 83.59% | 30.37 pp | $7M | 27% |
| Q4 2024 | 39 | +18% | 113.96% | 24.94 pp | $10M | 18% |
| Q3 2024 | 33 | 13% | 138.90% | 54.76 pp | $12M | 28% |
| Q2 2024 | 38 | β | 193.66% | β | $17M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying BOLT stock.
Based on Q1 2026 13F filings, institutional ownership of Bolt Biotherapeutics, Inc. stands at 28.4%, held across 23 reporting institutions.
Sofinnova Investments, Inc. is the largest reported institutional holder of BOLT, with approximately 137,721 shares worth $0.00B as of Q1 2026.
Yes β 3 widely-followed marquee investors appear among the top 25 institutional holders of BOLT, including RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC.
Our composite Smart Money Score for BOLT is 54 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
6 institutions opened new positions in BOLT during Q1 2026, while 4 fully exited. 4 added to existing positions and 13 trimmed.
BOLT institutional ownership fell by 9.21 percentage points quarter-over-quarter, with a net change of +2 holders.
The top 10 institutions account for 85.5% of all reported 13F value in BOLT, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Bolt Biotherapeutics, Inc. (BOLT) Institutional Ownership